$50 million Pre-Paid Advance Agreement and $5.5 million Promissory Note

Mainz Biomed (NASDAQ:MYNZ), a molecular genetics diagnostic company focused on early cancer detection, has announced a significant financial agreement with Yorkville Advisors Global. The $50 million Pre-Paid Advance Agreement (PPA) and $5.5 million Promissory Note (Note) will provide Mainz Biomed with the necessary funds to pursue its ambitious commercial and product development plans. Mainz Biomed Secures up to $50M in New Funding (globenewswire.com)

Guido Baechler, the CEO of Mainz Biomed, expressed the company’s excitement about the funding, emphasizing its strategic value and enabling the company to operate opportunistically. Mainz Biomed is currently marketing its flagship product, ColoAlert, a user-friendly test for colorectal cancer, in Europe and select international markets. The company is also conducting studies on novel gene expression biomarkers for colorectal cancer and pancreatic cancer.

Yorkville Advisors Global has opened new opportunities for the molecular genetics diagnostic company.

The funding agreement between $MYNZ and Yorkville Advisors Global has opened new opportunities for the molecular genetics diagnostic company. Mainz Biomed, known for its expertise in early cancer detection. Guido Baechler, the Chief Executive Officer of Mainz Biomed, expressed enthusiasm for the funding, recognizing its flexibility and potential for strategic growth. Mainz Biomed is well-positioned to pursue its ambitious commercial and product development plans. Currently, Mainz Biomed is actively marketing ColoAlert, its flagship product, which is an easy-to-use test for colorectal cancer. Additionally, the company is conducting studies on novel gene expression biomarkers for colorectal cancer and pancreatic cancer, with results expected in 2023. Home – Mainz Biomed